Bluemn et al.'s study revealed that both androgen receptor (AR) and neuroendocrine null PCa are notable for increased FGF and MAPK signaling pathways, and then FGF/MAPK blockade inhibited PCa growth in metastatic PCa with an AR-null phenotype [15]. The gene discussed is AR; the disease is posterior cortical atrophy.